Extracorporeal therapies in sepsis

Journal of Intensive Care Medicine

Volumn 28, Issue 5, 2013, Pages 281-295

  Panagiotou, Anthi ^a   Gaiao, Sérgio ^a,b   Cruz, Dinna N ^a,c  

^a SAN BORTOLO HOSPITAL   (Italy)

^b HOSPITAL DE SÃO JOÃO   (Portugal)

^c International Renal Research Institute (IRRIV)   (Italy)

Author keywords

adsorption; apoptosis; blood purification; cell based therapies; continuous renal replacement therapy; extracorporeal therapy; high cutoff membranes; high volume hemofiltration; inflammation; sepsis

Indexed keywords

CHEMOKINE; CYTOKINE;

ACUTE KIDNEY FAILURE; ADSORPTION; ARTICLE; BLOOD CLOTTING; CELL THERAPY; CLINICAL PRACTICE; COMPLEMENT SYSTEM; COUPLED PLASMA FILTRATION ADSORPTION; CYTOKINE ADSORBING COLUMNS; EXTRACORPOREAL IMMUNE SUPPORT SYSTEM; EXTRACORPOREAL OXYGENATION; HEMODIALYSIS; HEMOFILTRATION; HEMOPERFUSION; HIGH CUTOFF MEMBRANES; HIGH VOLUME HEMOFILTRATION; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; INTENSIVE CARE UNIT; LEUKOCYTE INHIBITION MODULE; MEDICAL DEVICE; MEDICAL PROCEDURES; MORBIDITY; MORTALITY; NONHUMAN; PATHOPHYSIOLOGY; PHAGOCYTOSIS; POLYMYXIN B COLUMN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REDUCTION; RENAL ASSIST DEVICE; RENAL REPLACEMENT THERAPY; SEPSIS;

ADSORPTION; APOPTOSIS; BLOOD PURIFICATION; CELL-BASED THERAPIES; CONTINUOUS RENAL REPLACEMENT THERAPY; EXTRACORPOREAL THERAPY; HIGH CUTOFF MEMBRANES; HIGH-VOLUME HEMOFILTRATION; INFLAMMATION; SEPSIS;

EXTRACORPOREAL CIRCULATION; HUMANS; INTENSIVE CARE; RENAL REPLACEMENT THERAPY; SEPSIS; SORPTION DETOXIFICATION;

EID: 84883427060     PISSN: 08850666     EISSN: 15251489     Source Type: Journal    
DOI: 10.1177/0885066611425759     Document Type: Article

References (132)

1. Bone RC, Sibbald WJ, Sprung CL. The ACCP-SCCM consensus conference on sepsis and organ failure. Chest. 1992 ; 101 (6). 1481-1483
2. Annane D, Bellissant E, Cavaillon JM. Septic shock. Lancet. 2005 ; 365 (9453). 63-78
3. Bagshaw SM, Lapinsky S, Dial S, et al. Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database Research Group Acute kidney injury in septic shock: clinical outcomes and impact of duration of hypotension prior to initiation of antimicrobial therapy. Intensive Care Med. 2009 ; 35 (5). 871-881
4. Ahlstrom A, Kuitunen A, Peltonen S, et al. Comparison of 2 acute renal failure severity scores to general scoring systems in the critically ill. Am J Kidney Dis. 2006 ; 48 (2). 262-268
5. Chertow GM, Burdick E, Honour M, Bonventre JV, Bates DW. Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. J Am Soc Nephrol. 2005 ; 16 (11). 3365-3370
6. House AA, Ronco C. Extracorporeal blood purification in sepsis and sepsis-related acute kidney injury. Blood Purif. 2008 ; 26 (1). 30-35
7. Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM consensus conference committee. American college of chest physicians/society of critical care medicine. Chest. 1992 ; 101 (6). 1644-1655
8. Camussi G, Montrucchio G, Dominioni L, Dionigi R. Septic shock-the unravelling of molecular mechanisms. Nephrol Dial Transplant. 1995 ; 10 (10). 1808-1813
9. Bellomo R, Ronco C. Indications and criteria for initiating renal replacement therapy in the intensive care unit. Kidney Int Suppl. 1998 ; 66: S106 - S109
10. Suffredini AF, Fromm RE, Parker MM, et al. The cardiovascular response of normal humans to the administration of endotoxin. N Engl J Med. 1989 ; 321 (5). 280-287
11. Dinarello CA, Cannon JG, Wolff SM, et al. Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1. J Exp Med. 1986 ; 163 (6). 1433-1450
12. van Deventer SJ, Buller HR, ten Cate JW, Aarden LA, Hack CE, Sturk A. Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic, and complement pathways. Blood. 1990 ; 76 (12). 2520-2526
13. Martich GD, Danner RL, Ceska M, Suffredini AF. Detection of interleukin 8 and tumor necrosis factor in normal humans after intravenous endotoxin: the effect of antiinflammatory agents. J Exp Med. 1991 ; 173 (4). 1021-1024
14. Michie HR, Manogue KR, Spriggs DR, et al. Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Med. 1988 ; 318 (23). 1481-1486
15. Suffredini AF, Harpel PC, Parrillo JE. Promotion and subsequent inhibition of plasminogen activation after administration of intravenous endotoxin to normal subjects. N Engl J Med. 1989 ; 320 (18). 1165-1172
16. Cavaillon JM, Munoz C, Fitting C, Misset B, Carlet J. Circulating cytokines: the tip of the iceberg?. Circ Shock. 1992 ; 38 (2). 145-152
17. Munoz C, Carlet J, Fitting C, Misset B, Bleriot JP, Cavaillon JM. Dysregulation of in vitro cytokine production by monocytes during sepsis. J Clin Invest. 1991 ; 88 (5). 1747-1754
18. Randow F, Syrbe U, Meisel C, et al. Mechanism of endotoxin desensitization: involvement of interleukin 10 and transforming growth factor beta. J Exp Med. 1995 ; 181 (5). 1887-1892
19. Brandtzaeg P, Osnes L, Ovstebo R, Joo GB, Westvik AB, Kierulf P. Net inflammatory capacity of human septic shock plasma evaluated by a monocyte-based target cell assay: identification of interleukin-10 as a major functional deactivator of human monocytes. J Exp Med. 1996 ; 184 (1). 51-60
20. Marie C, Muret J, Fitting C, Payen D, Cavaillon JM. Interleukin-1 receptor antagonist production during infectious and noninfectious systemic inflammatory response syndrome. Crit Care Med. 2000 ; 28 (7). 2277-2282
21. Granowitz EV, Porat R, Mier JW, et al. Intravenous endotoxin suppresses the cytokine response of peripheral blood mononuclear cells of healthy humans. J Immunol. 1993 ; 151 (3). 1637-1645
22. He X, Stuart JM. Prostaglandin E2 selectively inhibits human CD4+ T cells secreting low amounts of both IL-2 and IL-4. J Immunol. 1999 ; 163 (11). 6173-6179
23. Bone RC. Immunologic dissonance: a continuing evolution in our understanding of the systemic inflammatory response syndrome (SIRS) and the multiple organ dysfunction syndrome (MODS). Ann Intern Med. 1996 ; 125 (8). 680-687
24. Bone RC. The pathogenesis of sepsis. Ann Intern Med. 1991 ; 115 (6). 457-469
25. Bellomo R, Wan L, May C. Managing septic acute renal failure: "fill and spill"? "squeeze and diurese"? or "block Bax to the max"?. Crit Care Resusc. 2004 ; 6 (1). 12-16
26. Langenberg C, Bellomo R, May C, Wan L, Egi M, Morgera S. Renal blood flow in sepsis. Crit Care. 2005 ; 9 (4). R363 - R374
27. Wan L, Bagshaw SM, Langenberg C, Saotome T, May C, Bellomo R. Pathophysiology of septic acute kidney injury: what do we really know?. Crit Care Med. 2008 ; 36 (4 suppl). S198 - S203
28. Knotek M, Rogachev B, Wang W, et al. Endotoxemic renal failure in mice: role of tumor necrosis factor independent of inducible nitric oxide synthase. Kidney Int. 2001 ; 59 (6). 2243-2249
29. Cunningham PN, Dyanov HM, Park P, Wang J, Newell KA, Quigg RJ. Acute renal failure in endotoxemia is caused by TNF acting directly on TNF receptor-1 in kidney. J Immunol. 2002 ; 168 (11). 5817-5823
30. De Vriese AS, Vanholder RC, Pascual M, Lameire NH, Colardyn FA. Can inflammatory cytokines be removed efficiently by continuous renal replacement therapies?. Intensive Care Med. 1999 ; 25 (9). 903-910
31. Ronco C, Tetta C, Mariano F, et al. Interpreting the mechanisms of continuous renal replacement therapy in sepsis: the peak concentration hypothesis. Artif Organs. 2003 ; 27 (9). 792-801
32. De Vriese AS, Colardyn FA, Philippe JJ, Vanholder RC, De Sutter JH, Lameire NH. Cytokine removal during continuous hemofiltration in septic patients. J Am Soc Nephrol. 1999 ; 10 (4). 846-853
33. Costanzo MR, Guglin ME, Saltzberg MT, et al. UNLOAD Trial Investigators. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol. 2007 ; 49 (6). 675-683
34. Huang H, Yao T, Wang W, et al. Continuous ultrafiltration attenuates the pulmonary injury that follows open heart surgery with cardiopulmonary bypass. Ann Thorac Surg. 2003 ; 76 (1). 136-140
35. Davenport A. Renal replacement therapy in the patient with acute brain injury. Am J Kidney Dis. 2001 ; 37 (3). 457-466
36. Yekebas EF, Eisenberger CF, Ohnesorge H, et al. Attenuation of sepsis-related immunoparalysis by continuous veno-venous hemofiltration in experimental porcine pancreatitis. Crit Care Med. 2001 ; 29 (7). 1423-1430
37. Righetti M, Ferrario GM, Milani S, Serbelloni P, Sessa A. A single centre study about the effects of HFR on anemiac [in Italian]. G Ital Nefrol. 2004 ; 21 (suppl 30). S168 - S171
38. Krisper P, Stauber RE. Technology insight: artificial extracorporeal liver support-how does Prometheus compare with MARS?. Nat Clin Pract Nephrol. 2007 ; 3 (5). 267-276
39. Jeffrey RF, Khan AA, Prabhu P, et al. A comparison of molecular clearance rates during continuous hemofiltration and hemodialysis with a novel volumetric continuous renal replacement system. Artif Organs. 1994 ; 18 (6). 425-428
40. Kellum JA, Johnson JP, Kramer D, Palevsky P, Brady JJ, Pinsky MR. Diffusive vs. convective therapy: effects on mediators of inflammation in patient with severe systemic inflammatory response syndrome. Crit Care Med. 1998 ; 26 (12). 1995-2000
41. Brunet S, Leblanc M, Geadah D, Parent D, Courteau S, Cardinal J. Diffusive and convective solute clearances during continuous renal replacement therapy at various dialysate and ultrafiltration flow rates. Am J Kidney Dis. 1999 ; 34 (3). 486-492
42. Kellum JA, Angus DC, Johnson JP, et al. Continuous versus intermittent renal replacement therapy: a meta-analysis. Intensive Care Med. 2002 ; 28 (1). 29-37
43. Tonelli M, Manns B, Feller-Kopman D. Acute renal failure in the intensive care unit: a systematic review of the impact of dialytic modality on mortality and renal recovery. Am J Kidney Dis. 2002 ; 40 (5). 875-885
44. Mehta RL, McDonald B, Gabbai FB, et al. Collaborative Group for Treatment of ARF in the ICU. A randomized clinical trial of continuous versus intermittent dialysis for acute renal failure. Kidney Int. 2001 ; 60 (3). 1154-1163
45. Vinsonneau C, Camus C, Combes A, et al. Hemodiafe Study Group. Continuous venovenous haemodiafiltration versus intermittent haemodialysis for acute renal failure in patients with multiple-organ dysfunction syndrome: a multicentre randomised trial. Lancet. 2006 ; 368 (9533). 379-385
46. Cho KC, Himmelfarb J, Paganini E, et al. Survival by dialysis modality in critically ill patients with acute kidney injury. J Am Soc Nephrol. 2006 ; 17 (11). 3132-3138
47. Tarakcioglu M, Erbagci AB, Usalan C, Deveci R, Kocabas R. Acute effect of hemodialysis on serum levels of the proinflammatory cytokines. Mediators Inflamm. 2003 ; 12 (1). 15-19
48. Rabindranath K, Adams J, Macleod AM, Muirhead N. Intermittent versus continuous renal replacement therapy for acute renal failure in adults. Cochrane Database Syst Rev. 2007 ; 18 (3). CD003773
49. Lins RL, Elseviers MM, Van der Niepen P, et al. Intermittent versus continuous renal replacement therapy for acute kidney injury patients admitted to the intensive care unit: results of a randomized clinical trial. Nephrol Dial Transplant. 2009 ; 24 (2). 512-518
50. Uehlinger DE, Jakob SM, Ferrari P, et al. Comparison of continuous and intermittent renal replacement therapy for acute renal failure. Nephrol Dial Transplant. 2005 ; 20 (8). 1630-1637
51. Augustine JJ, Sandy D, Seifert TH, Paganini EP. A randomized controlled trial comparing intermittent with continuous dialysis in patients with ARF. Am J Kidney Dis. 2004 ; 44 (6). 1000-1007
52. John S, Griesbach D, Baumgartel M, Weihprecht H, Schmieder RE, Geiger H. Effects of continuous haemofiltration vs intermittent haemodialysis on systemic haemodynamics and splanchnic regional perfusion in septic shock patients: a prospective, randomized clinical trial. Nephrol Dial Transplant. 2001 ; 16 (2). 320-327
53. Dellinger RP, Levy MM, Carlet JM, et al;. International Surviving Sepsis Campaign Guidelines Committee; American Association of Critical-Care Nurses; American College of Chest Physicians; American College of Emergency Physicians; Canadian Critical Care Society; European Society of Clinical Microbiology and Infectious Diseases; European Society of Intensive Care Medicine; European Respiratory Society; International Sepsis Forum; Japanese Association for Acute Medicine; Japanese Society of Intensive Care Medicine; Society of Critical Care Medicine; Society of Hospital Medicine; Surgical Infection Society; World Federation of Societies of Intensive and Critical Care Medicine. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med. 2008 ; 36 (1). 296-327
54. Fiaccadori E, Maggiore U, Parenti E, et al. Sustained low-efficiency dialysis (SLED) with prostacyclin in critically ill patients with acute renal failure. Nephrol Dial Transplant. 2007 ; 22 (2). 529-537
55. Marshall MR, Golper TA, Shaver MJ, Alam MG, Chatoth DK. Urea kinetics during sustained low-efficiency dialysis in critically ill patients requiring renal replacement therapy. Am J Kidney Dis. 2002 ; 39 (3). 556-570
56. Van Biesen W, Veys N, Vanholder R. Intermittent hemodialysis for renal replacement therapy in intensive care: new evidence for old truths. Contrib Nephrol. 2007 ; 156: 304-308
57. Holt BG, White JJ, Kuthiala A, Fall P, Szerlip HM. Sustained low-efficiency daily dialysis with hemofiltration for acute kidney injury in the presence of sepsis. Clin Nephrol. 2008 ; 69 (1). 40-46
58. Ronco C, Bellomo R, Homel P, et al. Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. Lancet. 2000 ; 356 (9223). 26-30
59. Jun M, Heerspink HJ, Ninomiya T, et al. Intensities of renal replacement therapy in acute kidney injury: a systematic review and meta-analysis. Clin J Am Soc Nephrol. 2010 ; 5 (6). 956-963
60. Palevsky PM, Zhang JH, O'Connor TZ, et al. Intensity of renal support in critically ill patients with acute kidney injury. N Engl J Med. 2008 ; 359 (1). 7-20
61. Bellomo R, Cass A, Cole L, et al. Intensity of continuous renal-replacement therapy in critically ill patients. N Engl J Med. 2009 ; 361 (17). 1627-1638
62. Faulhaber-Walter R, Hafer C, Jahr N, et al. The hannover dialysis outcome study: comparison of standard versus intensified extended dialysis for treatment of patients with acute kidney injury in the intensive care unit. Nephrol Dial Transplant. 2009 ; 24 (7). 2179-2186
63. Van Wert R, Friedrich JO, Scales DC, Wald R, Adhikari NK. High-dose renal replacement therapy for acute kidney injury: systematic review and meta-analysis. Crit Care Med. 2010 ; 38 (5). 1360-1369
64. Palevsky PM. Renal support in acute kidney injury-how much is enough?. N Engl J Med. 2009 ; 361 (17). 1699-1701
65. Tolwani AJ, Campbell RC, Stofan BS, Lai KR, Oster RA, Wille KM. Standard versus high-dose CVVHDF for ICU-related acute renal failure. J Am Soc Nephrol. 2008 ; 19 (6). 1233-1238
66. Saudan P, Niederberger M, De Seigneux S, et al. Adding a dialysis dose to continuous hemofiltration increases survival in patients with acute renal failure. Kidney Int. 2006 ; 70 (7). 1312-1317
67. Jiang HL, Xue WJ, Li DQ, et al. Influence of continuous veno-venous hemofiltration on the course of acute pancreatitis. World J Gastroenterol. 2005 ; 11 (31). 4815-4821
68. Morgera S, Slowinski T, Melzer C, et al. Renal replacement therapy with high-cutoff hemofilters: impact of convection and diffusion on cytokine clearances and protein status. Am J Kidney Dis. 2004 ; 43 (3). 444-453
69. Bouman CS, Oudemans-Van Straaten HM, Tijssen JG, Zandstra DF, Kesecioglu J. Effects of early high-volume continuous venovenous hemofiltration on survival and recovery of renal function in intensive care patients with acute renal failure: a prospective, randomized trial. Crit Care Med. 2002 ; 30 (10). 2205-2211
70. Kellum JA, Ronco C. Dialysis: Results of RENAL-what is the optimal CRRT target dose?. Nat Rev Nephrol. 2010 ; 6 (4). 191-192
71. Damas P, Canivet JL, de Groote D, et al. Sepsis and serum cytokine concentrations. Crit Care Med. 1997 ; 25 (3). 405-412
72. Casey LC, Balk RA, Bone RC. Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann Intern Med. 1993 ; 119 (8). 771-778
73. Ratanarat R, Brendolan A, Piccinni P, et al. Pulse high-volume haemofiltration for treatment of severe sepsis: effects on hemodynamics and survival. Crit Care. 2005 ; 9 (4). R294 - R302
74. Ratanarat R, Brendolan A, Ricci Z, et al. Pulse high-volume hemofiltration in critically ill patients: a new approach for patients with septic shock. Semin Dial. 2006 ; 19 (1). 69-74
75. Ronco C, Bonello M, Bordoni V, et al. Extracorporeal therapies in non-renal disease: treatment of sepsis and the peak concentration hypothesis. Blood Purif. 2004 ; 22 (1). 164-174
76. Honore PM, Joannes-Boyau O, Gressens B. Blood and plasma treatments: the rationale of high-volume hemofiltration. Contrib Nephrol. 2007 ; 156: 387-395
77. Klouche K, Cavadore P, Portales P, Clot J, Canaud B, Beraud JJ. Continuous veno-venous hemofiltration improves hemodynamics in septic shock with acute renal failure without modifying TNFalpha and IL6 plasma concentrations. J Nephrol. 2002 ; 15 (2). 150-157
78. Honore PM, Joannes-Boyau O. High volume hemofiltration (HVHF) in sepsis: a comprehensive review of rationale, clinical applicability, potential indications and recommendations for future research. Int J Artif Organs. 2004 ; 27 (12). 1077-1082
79. Honore PM, Matson JR. Extracorporeal removal for sepsis: acting at the tissue level-the beginning of a new era for this treatment modality in septic shock. Crit Care Med. 2004 ; 32 (3). 896-897
80. Di Carlo JV, Alexander SR. Hemofiltration for cytokine-driven illnesses: the mediator delivery hypothesis. Int J Artif Organs. 2005 ; 28 (8). 777-786
81. Olszewski WL. The lymphatic system in body homeostasis: physiological conditions. Lymphat Res Biol. 2003 ; 1 (1). 11-21; discussion 21-14
82. Wasserman K, Mayerson HS. Dynamics of lymph and plasma protein exchange. Cardiologia. 1952 ; 21 (4). 296-307
83. Ghani RA, Zainudin S, Ctkong N, et al. Serum IL-6 and IL-1-ra with sequential organ failure assessment scores in septic patients receiving high-volume haemofiltration and continuous venovenous haemofiltration. Nephrology (Carlton). 2006 ; 11 (5). 386-393
84. Lonnemann G, Bechstein M, Linnenweber S, Burg M, Koch KM. Tumor necrosis factor-alpha during continuous high-flux hemodialysis in sepsis with acute renal failure. Kidney Int Suppl. 1999 ; (72). S84 - S87
85. Boussekey N, Chiche A, Faure K, et al. A pilot randomized study comparing high and low volume hemofiltration on vasopressor use in septic shock. Intensive Care Med. 2008 ; 34 (9). 1646-1653
86. Cole L, Bellomo R, Journois D, Davenport P, Baldwin I, Tipping P. High-volume haemofiltration in human septic shock. Intensive Care Med. 2001 ; 27 (6). 978-986
87. Joannes-Boyau O, Rapaport S, Bazin R, Fleureau C, Janvier G. Impact of high volume hemofiltration on hemodynamic disturbance and outcome during septic shock. ASAIO J. 2004 ; 50 (1). 102-109
88. Honore PM, Jamez J, Wauthier M, et al. Prospective evaluation of short-term, high-volume isovolemic hemofiltration on the hemodynamic course and outcome in patients with intractable circulatory failure resulting from septic shock. Crit Care Med. 2000 ; 28 (11). 3581-3587
89. Cornejo R, Downey P, Castro R, et al. High-volume hemofiltration as salvage therapy in severe hyperdynamic septic shock. Intensive Care Med. 2006 ; 32 (5). 713-722
90. Piccinni P, Dan M, Barbacini S, et al. Early isovolaemic haemofiltration in oliguric patients with septic shock. Intensive Care Med. 2006 ; 32 (1). 80-86
91. Arzuaga A, Isla A, Gascon AR, Maynar J, Corral E, Pedraz JL. Elimination of piperacillin and tazobactam by renal replacement therapies with AN69 and polysulfone hemofilters: evaluation of the sieving coefficient. Blood Purif. 2006 ; 24 (4). 347-354
92. Joannes-Boyau O, Honoré PM. Haemofiltration study: clinicaltrials.gov ID NCT00241228.. :
93. Mariano F, Fonsato V, Lanfranco G, et al. Tailoring high-cut-off membranes and feasible application in sepsis-associated acute renal failure: in vitro studies. Nephrol Dial Transplant. 2005 ; 20 (6). 1116-1126
94. Morgera S, Haase M, Kuss T, et al. Pilot study on the effects of high cutoff hemofiltration on the need for norepinephrine in septic patients with acute renal failure. Crit Care Med. 2006 ; 34 (8). 2099-2104
95. Haase M, Bellomo R, Baldwin I, et al. Hemodialysis membrane with a high-molecular-weight cutoff and cytokine levels in sepsis complicated by acute renal failure: a phase 1 randomized trial. Am J Kidney Dis. 2007 ; 50 (2). 296-304
96. Morgera S, Klonower D, Rocktaschel J, et al. TNF-alpha elimination with high cut-off haemofilters: a feasible clinical modality for septic patients?. Nephrol Dial Transplant. 2003 ; 18 (7). 1361-1369
97. Morgera S, Haase M, Rocktaschel J, et al. High permeability haemofiltration improves peripheral blood mononuclear cell proliferation in septic patients with acute renal failure. Nephrol Dial Transplant. 2003 ; 18 (12). 2570-2576
98. Haase M, Bellomo R, Morgera S, Baldwin I, Boyce N. High cut-off point membranes in septic acute renal failure: a systematic review. Int J Artif Organs. 2007 ; 30 (12). 1031-1041
99. Shoji H. Extracorporeal endotoxin removal for the treatment of sepsis: endotoxin adsorption cartridge (Toraymyxin). Ther Apher Dial. 2003 ; 7 (1). 108-114
100. Cruz DN, Bellomo R, Ronco C. Clinical effects of polymyxin B-immobilized fiber column in septic patients. Contrib Nephrol. 2007 ; 156: 444-451
101. Cantaluppi V, Assenzio B, Pasero D, et al. Polymyxin-B hemoperfusion inactivates circulating proapoptotic factors. Intensive Care Med. 2008 ; 34 (9). 1638-1645
102. Kumagai T, Takeyama N, Yabuki T, et al. Apheresis of activated leukocytes with an immobilized polymyxin B filter in patients with septic shock. Shock. 2010 ; 34 (5). 461-466
103. Cruz DN, de Cal M, Piccinni P, Ronco C. Polymyxin-B hemoperfusion and endotoxin removal: lessons from a review of the literature. Contrib Nephrol. 2010 ; 167: 77-82
104. Cruz DN, Perazella MA, Bellomo R, et al. Effectiveness of polymyxin B-immobilized fiber column in sepsis: a systematic review. Crit Care. 2007 ; 11 (2). R47
105. Cruz DN, Antonelli M, Fumagalli R, et al. Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA. 2009 ; 301 (23). 2445-2452
106. Vincent JL, Laterre PF, Cohen J, et al. A pilot-controlled study of a polymyxin B-immobilized hemoperfusion cartridge in patients with severe sepsis secondary to intra-abdominal infection. Shock. 2005 ; 23 (5). 400-405
107. Nakamura T, Kawagoe Y, Matsuda T, Koide H. Effect of polymyxin B-immobilized fiber on bone resorption in patients with sepsis. Intensive Care Med. 2004 ; 30 (9). 1838-1841
108. Nakamura T, Ushiyama C, Suzuki Y, et al. Combination therapy with polymyxin B-immobilized fibre haemoperfusion and teicoplanin for sepsis due to methicillin-resistant Staphylococcus aureus. J Hosp Infect. 2003 ; 53 (1). 58-63
109. Nakamura T, Ushiyama C, Suzuki Y, et al. Hemoperfusion with polymyxin B-immobilized fiber in septic patients with methicillin-resistant Staphylococcus aureus-associated glomerulonephritis. Nephron Clin Pract. 2003 ; 94 (2). C33 - C39
110. Nakamura T, Ushiyama C, Suzuki Y, Shoji H, Shimada N, Koide H. Hemoperfusion with polymyxin B immobilized fibers for urinary albumin excretion in septic patients with trauma. ASAIO J. 2002 ; 48 (3). 244-248
111. Suzuki H, Nemoto H, Nakamoto H, et al. Continuous hemodiafiltration with polymyxin-B immobilized fiber is effective in patients with sepsis syndrome and acute renal failure. Ther Apher. 2002 ; 6 (3). 234-240
112. Nemoto H, Nakamoto H, Okada H, et al. Newly developed immobilized polymyxin B fibers improve the survival of patients with sepsis. Blood Purif. 2001 ; 19 (4). 361-368;discussion 368-369
113. Nakamura T, Ebihara I, Shoji H, Ushiyama C, Suzuki S, Koide H. Treatment with polymyxin B-immobilized fiber reduces platelet activation in septic shock patients: decrease in plasma levels of soluble P-selectin, platelet factor 4 and beta-thromboglobulin. Inflamm Res. 1999 ; 48 (4). 171-175
114. Dellinger RP. Evaluating the use of polymyxin B in randomized controlled trial of adults treated for endotoxemia and septic shock clinicaltrials.gov ID NCT01046669.. :
115. Ronco C, Brendolan A, d'Intini V, Ricci Z, Wratten ML, Bellomo R. Coupled plasma filtration adsorption: rationale, technical development and early clinical experience. Blood Purif. 2003 ; 21 (6). 409-416
116. Mao HJ, Yu S, Yu XB, et al. Effects of coupled plasma filtration adsorption on immune function of patients with multiple organ dysfunction syndrome. Int J Artif Organs. 2009 ; 32 (1). 31-38
117. Lentini P, Cruz D, Nalesso F, et al. A pilot study comparing pulse high volume hemofiltration (pHVHF) and coupled plasma filtration adsorption (CPFA) in septic shock patients [in Italian]. G Ital Nefrol. 2009 ; 26 (6). 695-703
118. Taniguchi T. Cytokine adsorbing columns. Contrib Nephrol. 2010 ; 166: 134-141
119. Peng ZY, Carter MJ, Kellum JA. Effects of hemoadsorption on cytokine removal and short-term survival in septic rats. Crit Care Med. 2008 ; 36 (5). 1573-1577
120. Kobe Y, Oda S, Matsuda K, Nakamura M, Hirasawa H. Direct hemoperfusion with a cytokine-adsorbing device for the treatment of persistent or severe hypercytokinemia: a pilot study. Blood Purif. 2007 ; 25 (5-6). 446-453
121. Ding F, Humes HD. The bioartificial kidney and bioengineered membranes in acute kidney injury. Nephron Exp Nephrol. 2008 ; 109 (4). e118 - e122
122. Fissell WH, Lou L, Abrishami S, Buffington DA, Humes HD. Bioartificial kidney ameliorates gram-negative bacteria-induced septic shock in uremic animals. J Am Soc Nephrol. 2003 ; 14 (2). 454-461
123. Humes HD, Weitzel WF, Bartlett RH, et al. Initial clinical results of the bioartificial kidney containing human cells in ICU patients with acute renal failure. Kidney Int. 2004 ; 66 (4). 1578-1588
124. Tumlin J, Wali R, Williams W, et al. Efficacy and safety of renal tubule cell therapy for acute renal failure. J Am Soc Nephrol. 2008 ; 19 (5). 1034-1040
125. Mitzner SR, Freytag J, Sauer M, et al. Use of human preconditioned phagocytes for extracorporeal immune support: introduction of a concept. Ther Apher. 2001 ; 5 (5). 423-432
126. Sauer M, Altrichter J, Kreutzer HJ, et al. Extracorporeal cell therapy with granulocytes in a pig model of Gram-positive sepsis. Crit Care Med. 2009 ; 37 (2). 606-613
127. Altrichter J, Sauer M, Kaftan K, et al. Extracorporeal cell therapy of septic shock patients with donor granulocytes: a pilot study. Crit Care. 2011 ; 15 (2). R82
128. Scholz M, Cinatl J, Barros RT, et al. First efficacy and safety results with the antibody containing leukocyte inhibition module in cardiac surgery patients with neutrophil hyperactivity. ASAIO J. 2005 ; 51 (2). 144-147
129. Moreno JB, Margraf S, Schuller AM, Simon A, Moritz A, Scholz M. Inhibition of neutrophil activity in cardiac surgery with cardiopulmonary bypass: a novel strategy with the leukocyte inhibition module. Perfusion. 2004 ; 19 (1). 11-16
130. Scholz M, Cinatl J. Fas/FasL interaction: a novel immune therapy approach with immobilized biologicals. Med Res Rev. 2005 ; 25 (3). 331-342
131. Logters TT, Altrichter J, Paunel-Gorgulu A, et al. Extracorporeal immune therapy with immobilized agonistic anti-Fas antibodies leads to transient reduction of circulating neutrophil numbers and limits tissue damage after hemorrhagic shock/resuscitation in a porcine model. J Inflamm (Lond). 2010 ; 7: 18
132. Scholz M, Simon A, Berg M, et al. In vivo inhibition of neutrophil activity by a FAS (CD95) stimulating module: arterial in-line application in a porcine cardiac surgery model. J Thorac Cardiovasc Surg. 2004 ; 127 (6). 1735-1742